Domvanalimab, the most clinically advanced Fc-silent anti-TIGIT investigational monoclonal antibody, works by binding to TIGIT, which may activate the immune system to attack and destroy cancer cells and has demonstrated complete receptor coverage on all TIGIT-expressing peripheral leukocytes.
The Fc region on an antibody, when enabled, interacts with Fc receptors. This interaction can cause antibody-dependent cellular cytotoxicity (ADCC) and the depletion of peripheral immune cells, such as regulatory T cells, which are critical for desired antitumor activity. Domvanalimab has a silent Fc domain, which does not interact with Fc receptors to deplete TIGIT-expressing immune cells and may retain immune cells to attack cancer.
Domvanalimab, in combination with zimberelimab, an investigational anti-PD-1 antibody, is being investigated in Phase 3 clinical trials.